{"disease":{"id":"metastatic-squamous-cell-carcinoma","name":"metastatic squamous cell carcinoma"},"drugs":{"marketed":[{"drug_id":"tislelizumab","indication_name":"Unresectable or metastatic esophageal squamous cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tevimbra","generic_name":"TISLELIZUMAB","company_name":"Beigene","drug_phase":"marketed","molecular_target":"Pd-1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"900","mechanism":"Tevimbra blocks the PD-1 receptor, allowing the immune system to recognize and attack cancer cells."},{"drug_id":"tislelizumab","indication_name":"Unresectable or metastatic esophageal squamous cell carcinoma (ESCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tevimbra","generic_name":"TISLELIZUMAB","company_name":"Beigene","drug_phase":"marketed","molecular_target":"Pd-1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"900","mechanism":"Tevimbra blocks the PD-1 receptor, allowing the immune system to recognize and attack cancer cells."},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic cutaneous squamous cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"cosibelimab","indication_name":"metastatic cutaneous squamous cell carcinoma (mCSCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unloxcyt","generic_name":"COSIBELIMAB","company_name":"Checkpoint Therapeutics Inc","drug_phase":"marketed","molecular_target":"Pd-1","drug_class":"Programmed Death Ligand-1 Blocker [EPC]","quality_score":10,"revenue":null,"mechanism":"Unloxcyt blocks the PD-1/PD-L1 pathway to help the immune system recognize and attack cancer cells."},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) in combination with 5-fluorouracil.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"chembl-chembl1789844","indication_name":"Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IPILIMUMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"disitamab-vedotin","indication_name":"Locally advanced or metastatic esophageal squamous cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Disitamab vedotin","generic_name":"disitamab-vedotin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"human epidermal growth factor receptor 2 (HER2)","drug_class":"antibody-drug conjugate","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic esophageal squamous cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":8,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05176483","title":"Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":1314,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT05142709","title":"Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.","phase":"","overall_status":"COMPLETED","enrollment_count":1197,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT03896958","title":"The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"SpeciCare","has_results":false},{"nct_id":"NCT04949256","title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":864,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT02834013","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":818,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05038254","title":"Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":750,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02369874","title":"Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":736,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT06190652","title":"Real-world Experience of ICIs Plus Chemotherapy With or Without Radiotherapy for Advanced ESCC.","phase":"","overall_status":"COMPLETED","enrollment_count":728,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT05078047","title":"Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":646,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT04187352","title":"A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":540,"lead_sponsor_name":"CStone Pharmaceuticals","has_results":false},{"nct_id":"NCT06356272","title":"Oropharynx (OPX) Biomarker Trial","phase":"","overall_status":"RECRUITING","enrollment_count":440,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05063552","title":"Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":430,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02499328","title":"Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":340,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT03866382","title":"Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":314,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07090499","title":"A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":310,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT04181060","title":"Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05721755","title":"Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":290,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT02319044","title":"Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":267,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT05620134","title":"Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":263,"lead_sponsor_name":"Salubris Biotherapeutics Inc","has_results":false},{"nct_id":"NCT03645928","title":"Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":245,"lead_sponsor_name":"Iovance Biotherapeutics, Inc.","has_results":false},{"nct_id":"NCT04444921","title":"EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":205,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06592716","title":"Can Recurrence of Cancer in the Oropharynx be Detected by Blood Samples?","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT05815927","title":"Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"European Organisation for Research and Treatment of Cancer - EORTC","has_results":false},{"nct_id":"NCT04785820","title":"A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":190,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT04799054","title":"A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":188,"lead_sponsor_name":"Ascendis Pharma Oncology Division A/S","has_results":false},{"nct_id":"NCT01602315","title":"A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":179,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT05075980","title":"Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":174,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05094804","title":"A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":172,"lead_sponsor_name":"OncoResponse, Inc.","has_results":false},{"nct_id":"NCT04140500","title":"Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":170,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT03809624","title":"Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":160,"lead_sponsor_name":"Inhibrx Biosciences, Inc","has_results":false},{"nct_id":"NCT07405086","title":"Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":160,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT02376699","title":"Safety Study of SEA-CD40 in Cancer Patients","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":159,"lead_sponsor_name":"Seagen Inc.","has_results":false},{"nct_id":"NCT06589804","title":"Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":158,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02721732","title":"Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":157,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT07390838","title":"A Study of SH009 Injection in Patients With Advanced Solid Tumors.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Nanjing Sanhome Pharmaceutical, Co., Ltd.","has_results":false},{"nct_id":"NCT05136196","title":"BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04282109","title":"Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":141,"lead_sponsor_name":"Grupo Español de Tratamiento de Tumores de Cabeza y Cuello","has_results":true},{"nct_id":"NCT03708328","title":"A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":134,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT05269381","title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT02245100","title":"Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":130,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","has_results":false},{"nct_id":"NCT05512520","title":"Concurrent Chemoradiotherapy for Stage IVB Esophageal Squamous Cell Carcinoma（EC-CRT-003）","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":126,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT01064479","title":"Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":123,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT07280377","title":"A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":122,"lead_sponsor_name":"Oncolytics Biotech","has_results":false},{"nct_id":"NCT06662058","title":"Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation","phase":"NA","overall_status":"RECRUITING","enrollment_count":118,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT04310007","title":"Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":117,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00454779","title":"PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":113,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT02207530","title":"Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":112,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT03665285","title":"A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":109,"lead_sponsor_name":"NextCure, Inc.","has_results":true},{"nct_id":"NCT04272034","title":"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":105,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT03904927","title":"Local Therapy for Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":104,"lead_sponsor_name":"Fudan University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}